media – Page 122 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Breaking the Waves with “Dao, Fa, and Shu”

In the vast sea of stars in the biopharmaceutical industry, Novartis is like a giant ship sailing through the wind and waves, with technological innovation as the sail and strategic determination as the anchor, opening up a unique route. Recently, a reporter from Shanghai Securities News walked into the headquarters and R&D center of Nuotai Biotechnology, and through a conversation with the company’s chairman Tong Ziquan, explored the growth logic of this science and technology innovation board enterprise. In recent years, Novartis has made significant achievements in the fields of peptides, oligonucleotides, and small molecule pharmaceuticals. The company has overcome the challenge of large-scale production of long-chain peptides, and with the increasing volume of products such as semaglutide, its demand for peptide raw material procurement will significantly increase in 2024. At the same time, the company has been forward-looking in the field of oligonucleotides since 2022 and has rapidly formed ...
- Source: drugdu
- 234
- March 17, 2025
World First! One innovative medical device approved for market launch

Recently, the National Medical Products Administration approved the registration application for the innovative product “Transcatheter Tricuspid Ring Forming System” of Shanghai Huihe Medical Technology Co., Ltd. (hereinafter referred to as Huihe Medical). Rich pipelines, multiple pioneering products launched Huihe Medical was founded in 2019 and is a world leading cardiovascular intervention platform company with independent innovation capabilities. At present, Huihe Medical has four major platforms including delivery systems, clinical medical technology, precision manufacturing, and global marketing, all of which have industry-leading advantages. We have independently developed and world leading related products in the fields of heart valve intervention, vascular intervention, electrophysiological intervention, drug delivery intervention, and intelligent intervention. The K-Clip approved for listing this time ® The transcatheter tricuspid annuloplasty system is the world’s first transcatheter tricuspid annulus repair system independently developed by Huihe Medical, filling the gap in the field of tricuspid valve intervention in China and used to ...
- Source: drugdu
- 327
- March 17, 2025
Over 27.6 billion! The rise of Chinese medicine giants under the “China Resources” brand

According to the announcement, China Resources Sanjiu achieved a total revenue of approximately 27.617 billion yuan in 2024, a year-on-year increase of 11.63%; The net profit attributable to shareholders of the listed company is approximately 3.368 billion yuan, a year-on-year increase of 18.05. Specifically, in terms of quarterly performance, from the first quarter to the fourth quarter of 2024, China Resources Sanjiu achieved operating revenues of 7.294 billion yuan, 6.812 billion yuan, 5.634 billion yuan, and 7.876 billion yuan, respectively, with net profits of 1.364 billion yuan, 1.034 billion yuan, 561 million yuan, and 408 million yuan. In the fourth quarter, China Resources Sanjiu’s revenue increased by about 28.5% year-on-year, while its net profit decreased by 10.3% year-on-year. Behind the numbers lies not only the growth trajectory of a company, but also the wave of the times in China’s pharmaceutical industry driven by policy guidance, market changes, and innovation. 01. ...
- Source: drugdu
- 291
- March 17, 2025
【EXPERT Q&A】What are the special environmental and facility requirements for the self-testing laboratory of IVD products?

Drugdu.com expert’s response: The self-testing laboratories for IVD (In Vitro Diagnostic) products have a series of specific requirements in terms of environment and facilities, which aim to ensure the safety, accuracy, and compliance of the laboratories. Below is a detailed summary of these requirements: I. Environmental Requirements Cleanliness: The cleanliness of the laboratory must meet the ISO 14644-1 standard, typically ISO 7 or ISO 8 class, to reduce particulate and microbial contamination. This helps ensure the accuracy and reliability of experimental results. Temperature and Humidity Control: The temperature is generally controlled between 20-25°C, and humidity between 30%-60%. Stable temperature and humidity conditions contribute to the normal operation of experimental equipment and the stability of experimental results. Biosafety: Depending on the type of experiments, the laboratory must comply with BSL-1 or BSL-2 (Biosafety Level Laboratory) standards. This includes setting up biosafety cabinets, installing HEPA filters, and other measures to prevent contamination ...
- Source: drugdu
- 227
- March 17, 2025
How Can AI Empower Medical B2B Trade? A Must-Try Industry Assistant

I. How Can AI Empower Medical B2B Trade? In global pharmaceutical and medical device B2B trade, challenges such as information opacity, complex compliance requirements, unpredictable market trends, and cross-border trade barriers have long troubled industry users. Businesses often invest significant time and effort in researching regulations, analyzing market data, and assessing procurement risks—precisely where AI can play a vital role. The launch of Drugdu AI marks a breakthrough in the application of AI in the pharmaceutical B2B sector. Developed by Drugdu.com, this intelligent industry assistant is powered by DeepSeek AI technology, designed to provide users with precise industry insights, regulatory guidance, and market trend analysis, ultimately optimizing procurement and supply chain decisions. But is Drugdu AI truly practical? What scenarios does it apply to? How accurate are its AI-generated responses? We conducted in-depth testing and summarized some practical usage recommendations for industry users. II. Drugdu AI Hands-on Experience: Core Feature Breakdown We ...
- Source: drugdu
- 554
- March 17, 2025
Utilizing stem cells to create a new type of vascular graft, the ‘universal life pipeline’, to promote progress in related surgeries

In a study published in the latest issue of Cell Reports Medicine, scientists from the National Primate Research Center in Wisconsin and the University of Wisconsin Madison demonstrated a “universal life pipeline” – a novel small-diameter vascular graft developed using stem cell-derived arterial endothelial cells (AECs). This achievement is of great significance for advancing research in biotechnology and vascular surgery. Blood vessels are known as the “life vessels” of the human body. Currently, synthetic vascular grafts have been widely used for repairing large blood vessels, but for small diameter vessels such as those used in coronary artery bypass surgery, the existing options are very limited. The usual method is to extract blood vessels from other parts of the patient’s body, but this is not only highly invasive, but also limited by the number and quality of available blood vessels, especially when the patient has comorbidities. Another method is to use ...
- Source: drugdu
- 224
- March 14, 2025
Sunshine Novo and Anlong Biotech use small nucleic acid siRNA technology to tackle the development challenges of cardiovascular and cerebrovascular drugs!

Sunshine Novo and Anlong Biotechnology have officially reached a project and strategic cooperation to jointly promote the application of small nucleic acid siRNA technology platform in the field of cardiovascular and cerebrovascular treatment, and develop an innovative small nucleic acid (siRNA) drug in this field. This collaboration will leverage the unique advantages of siRNA technology to address pain points in current disease treatments, provide patients with longer lasting and more convenient treatment options, and promote innovation and development of small nucleic acid drugs in the field of cardiovascular and cerebrovascular chronic disease treatment. Breakthrough advantages of siRNA technology SiRNA technology, as an emerging therapeutic approach, has shown great potential in the field of chronic disease treatment in recent years. SiRNA drugs achieve long-lasting treatment by targeting specific mRNA molecules and inhibiting the expression of disease-related proteins. Compared with traditional daily medication, siRNA drugs can be administered quarterly or semi annually, ...
- Source: drugdu
- 274
- March 14, 2025
single unit price reduction of 91%

In January 2025, the Guizhou Provincial Health Commission officially launched the public bidding process for the Guizhou Provincial Regional Medical Center Equipment Renewal Project (Phase I). The total budget of this project exceeds 578 million yuan, covering CT MRI、 Ultrasound DSA、 There are dozens of categories of medical equipment such as endoscopes and medical linear accelerators. Ultrasound imaging diagnostic equipment has become a key area for procurement cost savings, with the winning bid for the Consona N9T ultrasound single device being only 210000 yuan. Compared to the budgeted price, the cost savings rate is as high as 91.25%. 01. Ultrasound: a key focus of procurement cost savings This public bidding project has undergone strict evaluation and bidding processes. Except for project 10 and project 14, which were disqualified due to reasons, the winning results of the remaining sub projects have been announced recently. It is noteworthy that during the bidding ...
- Source: drugdu
- 255
- March 14, 2025
3.9 billion! Innovative pharmaceutical giants make another breakthrough

On March 9th, Baili Tianheng released the “2025 Plan for Issuing A-shares to Specific Targets”, which showed that the company plans to issue A-shares to specific targets and raise no more than 3.9 billion yuan (including the main amount). After deducting the issuance expenses, the actual raised funds will be used entirely for innovative drug research and development projects. Affected by this news, on March 10th, the stock price of Baili Tianheng rose slightly by 0.97%, closing at 213.05 yuan per share, with a total market value of 85.4 billion yuan. There is nearly 5 billion yuan in cash lying on the account, but it still needs to raise funds through both A-share and Hong Kong stock platforms. This seemingly contradictory capital operation contains the survival rules and strategic ambitions of Chinese innovative pharmaceutical companies in global competition. 1. Five billion yuan in cash is difficult to fill the research ...
- Source: drugdu
- 192
- March 14, 2025
【EXPERT Q&A】How does Ibrutinib work?

Drugdu.com expert’s response: Ibrutinib demonstrates remarkable therapeutic efficacy, particularly in the treatment of various hematological malignancies. Below is a detailed analysis of its therapeutic effects: I. Primary Effects and Functions Inhibition of Malignant B-Cell Proliferation and Survival: Ibrutinib, as an inhibitor of Bruton’s tyrosine kinase (BTK), effectively inhibits BTK enzymatic activity by forming a covalent bond with the cysteine residue at the BTK active site, thereby blocking growth and survival signals in tumor cells. Reduction in B-Cell Migration and Adhesion In Vitro: By inhibiting BTK-mediated signaling pathways, ibrutinib further weakens the ability of malignant B-cells to spread and invade within the body, aiding in controlling disease progression. Improvement in Patient Prognosis and Quality of Life: For patients who have failed one or more lines of prior therapy, ibrutinib offers a new treatment option and extends patient survival. Additionally, it significantly improves patient symptoms, such as lymphadenopathy and fatigue, thereby enhancing ...
- Source: drugdu
- 218
- March 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.